Allogene Therapeutics Inc (ALLO) Stock Price, Quote & News

Company Profile

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineer...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 457 2700

Website: allogene.com

Address:

210 East Grand Avenue, South San Francisco, United States

Taurusthebullman Mar. 20 at 7:14 PM

$ALLO sorry for the love of God make it stop.. the whole market please stop falling

0 · Reply

Taurusthebullman Mar. 18 at 1:57 PM

$ALLO wow they're really playing with this one

2 · Reply

Unburdened Mar. 18 at 3:07 AM

$ALLO Really?? WTF.... I hope the shorts fry

0 · Reply

Tomc120000 Mar. 17 at 7:30 PM

$ALLO seems Shorts out smart me every time!!

0 · Reply

Diggit Mar. 17 at 3:32 PM

$ALLO shorts playing a dangerous game. Their time is limited. Better cover soon

0 · Reply

EarningsCentral Mar. 15 at 3:03 AM

$ALLO Q4 2025 Earnings | ALPHA3 Data Could Transform CAR-T for Lymphoma https://youtu.be/ViMt3MyGMfo

0 · Reply

aboutblank84 Mar. 14 at 12:22 PM

$ALLO this was market related pulldown and not Allogene. You couldn’t have asked for more. Cas runway extended to 2028. In between the lines, they’re basically saying that MRD delta of minimum 25% is a done deal, question is not whether this will work, it’s how well it will work, could it even be curative? We’ll know much more in 12-20 trading days

0 · Reply

erevnon Mar. 13 at 6:28 PM

Piper Sandler maintains Allogene Therapeutics $ALLO at Overweight and raises the price target from $7 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Taurusthebullman Mar. 13 at 3:20 PM

$ALLO oh man, after all that good news? What the frak....

1 · Reply

Unburdened Mar. 13 at 1:05 AM

$ALLO Lots of analysts questions. Not sure I have seen this much coverage of $ALLO. Feel we have tremendous momentum after the conference call. Now let's see some great results in April and off we go to $10.

1 · Reply

Allogene Therapeutics, Inc. (ALLO) Q4 2025 Earnings Call Transcript

Mar 12, 2026, 4:02 PM EDT - 9 days ago

Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

Mar 2, 2026, 8:30 AM EST - 19 days ago

Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update

Feb 18, 2026, 3:04 PM EST - 4 weeks ago

Allogene Therapeutics, Inc. (ALLO) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript

Feb 5, 2026, 8:30 AM EST - 6 weeks ago

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Jan 8, 2026, 8:30 AM EST - 2 months ago

Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T

Dec 15, 2025, 5:39 PM EST - 3 months ago

Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis

CLLS

Nov 7, 2025, 6:08 PM EST - 4 months ago

Allogene: ALLO-316 Data In RCC Could Lead To Targeting Solid Tumors With CAR T

Nov 7, 2025, 12:16 AM EST - 4 months ago

Allogene Therapeutics, Inc. (ALLO) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:05 PM EST - 4 months ago

Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update

Nov 3, 2025, 9:04 AM EST - 4 months ago

Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting

Oct 30, 2025, 8:30 AM EDT - 5 months ago

Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update

Oct 4, 2025, 12:22 AM EDT - 6 months ago

Allogene Therapeutics, Inc. (ALLO) Presents at Citi's SMID Call Series 2025 Transcript

Aug 27, 2025, 8:30 AM EDT - 7 months ago

Allogene Therapeutics Announces Participation in Upcoming Investor Conference

Aug 14, 2025, 3:02 PM EDT - 7 months ago

Allogene Therapeutics: Important Catalysts Guided For Early 2026

Aug 13, 2025, 9:13 PM EDT - 7 months ago

Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 4:05 PM EDT - 7 months ago

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

Aug 6, 2025, 8:30 AM EDT - 8 months ago

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

Aug 1, 2025, 8:30 AM EDT - 8 months ago

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

Jun 1, 2025, 10:45 AM EDT - 10 months ago

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

May 29, 2025, 3:37 PM EDT - 10 months ago

Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment

May 28, 2025, 9:43 AM EDT - 10 months ago

Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade)

May 22, 2025, 5:17 PM EDT - 10 months ago

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

May 13, 2025, 10:47 PM EDT - 11 months ago

Allogene Therapeutics, Inc. (ALLO) Q1 2025 Earnings Call Transcript

May 13, 2025, 4:05 PM EDT - 11 months ago

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

May 6, 2025, 8:30 AM EDT - 11 months ago

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

Apr 23, 2025, 10:12 AM EDT - 11 months ago

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 7, 2025, 8:30 AM EDT - 1 year ago

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Mar 13, 2025, 11:56 PM EDT - 1 year ago

Allogene Therapeutics, Inc. (ALLO) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 4:02 PM EDT - 1 year ago

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Mar 3, 2025, 8:30 AM EST - 1 year ago

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Feb 26, 2025, 10:52 AM EST - 1 year ago

Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities

Feb 26, 2025, 8:30 AM EST - 1 year ago

Allogene Therapeutics Announces Participation in March Investor Conference

Feb 25, 2025, 4:10 PM EST - 1 year ago

Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

Feb 24, 2025, 10:53 PM EST - 1 year ago

Allogene Therapeutics: Disrupting CAR-T With A Scalable Model

$Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology$

Feb 13, 2025, 4:30 PM EST - 1 year ago

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

Jan 28, 2025, 8:30 AM EST - 1 year ago

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

Dec 16, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 12, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

Nov 19, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics Announces Participation in December Investor Conferences

Nov 18, 2024, 8:30 AM EST - 1 year ago

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

Nov 7, 2024, 8:59 PM EST - 1 year ago

Allogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:02 PM EST - 1 year ago

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

Nov 7, 2024, 10:00 AM EST - 1 year ago

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

Nov 5, 2024, 9:10 AM EST - 1 year ago

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 30, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

Oct 2, 2024, 4:11 PM EDT - 1 year ago

Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Activity

Sep 30, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

Aug 26, 2024, 11:39 PM EDT - 1 year ago

Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies

Aug 10, 2024, 12:34 AM EDT - 1 year ago

Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call Transcript

Taurusthebullman Mar. 20 at 7:14 PM

$ALLO sorry for the love of God make it stop.. the whole market please stop falling

0 · Reply

Taurusthebullman Mar. 18 at 1:57 PM

$ALLO wow they're really playing with this one

2 · Reply

Unburdened Mar. 18 at 3:07 AM

$ALLO Really?? WTF.... I hope the shorts fry

0 · Reply

Tomc120000 Mar. 17 at 7:30 PM

$ALLO seems Shorts out smart me every time!!

0 · Reply

Diggit Mar. 17 at 3:32 PM

$ALLO shorts playing a dangerous game. Their time is limited. Better cover soon

0 · Reply

EarningsCentral Mar. 15 at 3:03 AM

$ALLO Q4 2025 Earnings | ALPHA3 Data Could Transform CAR-T for Lymphoma https://youtu.be/ViMt3MyGMfo

0 · Reply

aboutblank84 Mar. 14 at 12:22 PM

0 · Reply

erevnon Mar. 13 at 6:28 PM

Piper Sandler maintains Allogene Therapeutics $ALLO at Overweight and raises the price target from $7 to https://marketsblock.com/stock-upgrades-and-downgrades/

0 · Reply

Taurusthebullman Mar. 13 at 3:20 PM

$ALLO oh man, after all that good news? What the frak....

1 · Reply

Unburdened Mar. 13 at 1:05 AM

1 · Reply

StocktwitsEarnings Mar. 12 at 9:23 PM

$ALLO Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.17 up 39.29% YoY • Allogene Therapeutics expects its cash, cash equivalents, and investments to fund operations into Q1 2028, and anticipates ALPHA3 trial enrollment completion by end of 2027, with initial proof-of-concept data for ALLO-329 expected in June 2026.

1 · Reply

Taurusthebullman Mar. 12 at 8:56 PM

$ALLO it is great news I just hope the red sea of the market from today doesn't pull it down for where it should be too much

1 · Reply

AlexandreDumas Mar. 12 at 8:55 PM

$ALLO Great news

0 · Reply

Unburdened Mar. 12 at 8:34 PM

$ALLO Cash runway till Q1 2028. Nice. Positive press release. Waiting for CC

0 · Reply

Maximusprime69 Mar. 12 at 7:55 PM

$ALLO Locked and loaded for earnings

0 · Reply

Taurusthebullman Mar. 11 at 6:05 PM

$ALLO I've always had good luck with Thursday after close ERs .. let's hope this is a good one tomorrow evening...cmon Allo

0 · Reply

aboutblank84 Mar. 11 at 7:02 AM

$ALLO I see some say it might drop on good data. No. This is going to be a repricing event. Currently it’s trading as if it won’t work. If they post data this will shoot up and stay up. After April data we’ll get analyst upgrades, we’ll be in the anticipation phase for cemacel data in June and I suspect buyout rumors will start to flourish. This is one of (if not the most) undervalued risk/reward opportunities of the whole market 🚀

0 · Reply

AlexRo777 Mar. 10 at 11:23 PM

$ALLO i sold at 2.3$ quite low to be honest, but I was scared of earnings, even tho data is amazing here for sure, I was worried about the cash flow situation. Hope it doesn’t skyrocket on earnings I will be so upset because the stock that I bought when I sold allo it’s going down recently. I was holding this for 2 years if I sold at a breakout point I will regret it forever…

3 · Reply

Stackdoe101 Mar. 10 at 4:51 PM

$ALLO

0 · Reply

GangsterX Mar. 10 at 2:24 PM

$ALLO this stock has data pending and it can be out anytime and i sold half before data. I think data will be good but it can drop on good data.

1 · Reply

ms82494 Mar. 9 at 11:46 PM

$ALLO, $CRBU Very compelling strength from the allogeneic CAR-T stocks, today. Seems like conviction is spreading, as catalysts approach.

0 · Reply

gatormike12 Mar. 9 at 9:22 PM

$ALLO Looks like there is a buyout happening here. Look what happened to $TALK

0 · Reply

Market Cap	524.12M
Revenue (ttm)	0.00
Net Income (ttm)	-190.89M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	20,747,701
Avg Vol	6,112,238
Day's Range	N/A - N/A
Shares Out	243.78M
Stochastic %K	2%
Beta	0.50
Analysts	Strong Sell
Price Target	$7.47